TnI-Ultra assay measurements in cancer patients

Comparison with the conventional assay and clinical implication

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The serial monitoring of cardiac troponin represents an effective approach for the early identification, assessment, and monitoring of chemotherapy-induced cardiac injury. Over the last few years new generations of troponin assays, referred to as sensitive and high sensitivity assays, able to detect very low concentrations of troponin, have been progressively released on different platforms. Some studies have assessed the comparability of the cTnI measurements with the new assays versus the conventional ones, but none of these in the oncological population. We compared the cTnI results determined on Stratus CS and ADVIA Centaur CP System in 70 breast cancer patients, for a total of 327 samples collected during different cycles of treatment. Correlation (Spearman = 0.732) and agreement (91.4%) between the assays were good (244 concordant negatives and 55 concordant positives), with a frequency of 8.6% discordant results among the cTnI measurements. Despite the well-known lack in the harmonization and standardization of the currently commercially available cTnI methods, we found a good clinical concordance of cTnI determination on both systems.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume74
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Troponin
Assays
Neoplasms
Chemotherapy
Monitoring
Standardization
Breast Neoplasms
Drug Therapy
Wounds and Injuries
Population
Therapeutics

Keywords

  • Biomarkers
  • Cardiotoxicity
  • Concordance
  • Method evaluation
  • Oncological setting

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Medicine(all)

Cite this

@article{05aa2caa68e44f08a3ced7ae7bf5d284,
title = "TnI-Ultra assay measurements in cancer patients: Comparison with the conventional assay and clinical implication",
abstract = "The serial monitoring of cardiac troponin represents an effective approach for the early identification, assessment, and monitoring of chemotherapy-induced cardiac injury. Over the last few years new generations of troponin assays, referred to as sensitive and high sensitivity assays, able to detect very low concentrations of troponin, have been progressively released on different platforms. Some studies have assessed the comparability of the cTnI measurements with the new assays versus the conventional ones, but none of these in the oncological population. We compared the cTnI results determined on Stratus CS and ADVIA Centaur CP System in 70 breast cancer patients, for a total of 327 samples collected during different cycles of treatment. Correlation (Spearman = 0.732) and agreement (91.4{\%}) between the assays were good (244 concordant negatives and 55 concordant positives), with a frequency of 8.6{\%} discordant results among the cTnI measurements. Despite the well-known lack in the harmonization and standardization of the currently commercially available cTnI methods, we found a good clinical concordance of cTnI determination on both systems.",
keywords = "Biomarkers, Cardiotoxicity, Concordance, Method evaluation, Oncological setting",
author = "Michela Salvatici and Daniela Cardinale and Edoardo Botteri and Vincenzo Bagnardi and Cristian Mauro and Cassatella, {Maria C.} and Paola Lentati and Fabio Bottari and Laura Zorzino and Rita Passerini and Cipolla, {Carlo M.} and Sandri, {Maria T.}",
year = "2014",
doi = "10.3109/00365513.2014.898325",
language = "English",
volume = "74",
pages = "385--391",
journal = "Scandinavian Journal of Clinical and Laboratory Investigation",
issn = "0036-5513",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - TnI-Ultra assay measurements in cancer patients

T2 - Comparison with the conventional assay and clinical implication

AU - Salvatici, Michela

AU - Cardinale, Daniela

AU - Botteri, Edoardo

AU - Bagnardi, Vincenzo

AU - Mauro, Cristian

AU - Cassatella, Maria C.

AU - Lentati, Paola

AU - Bottari, Fabio

AU - Zorzino, Laura

AU - Passerini, Rita

AU - Cipolla, Carlo M.

AU - Sandri, Maria T.

PY - 2014

Y1 - 2014

N2 - The serial monitoring of cardiac troponin represents an effective approach for the early identification, assessment, and monitoring of chemotherapy-induced cardiac injury. Over the last few years new generations of troponin assays, referred to as sensitive and high sensitivity assays, able to detect very low concentrations of troponin, have been progressively released on different platforms. Some studies have assessed the comparability of the cTnI measurements with the new assays versus the conventional ones, but none of these in the oncological population. We compared the cTnI results determined on Stratus CS and ADVIA Centaur CP System in 70 breast cancer patients, for a total of 327 samples collected during different cycles of treatment. Correlation (Spearman = 0.732) and agreement (91.4%) between the assays were good (244 concordant negatives and 55 concordant positives), with a frequency of 8.6% discordant results among the cTnI measurements. Despite the well-known lack in the harmonization and standardization of the currently commercially available cTnI methods, we found a good clinical concordance of cTnI determination on both systems.

AB - The serial monitoring of cardiac troponin represents an effective approach for the early identification, assessment, and monitoring of chemotherapy-induced cardiac injury. Over the last few years new generations of troponin assays, referred to as sensitive and high sensitivity assays, able to detect very low concentrations of troponin, have been progressively released on different platforms. Some studies have assessed the comparability of the cTnI measurements with the new assays versus the conventional ones, but none of these in the oncological population. We compared the cTnI results determined on Stratus CS and ADVIA Centaur CP System in 70 breast cancer patients, for a total of 327 samples collected during different cycles of treatment. Correlation (Spearman = 0.732) and agreement (91.4%) between the assays were good (244 concordant negatives and 55 concordant positives), with a frequency of 8.6% discordant results among the cTnI measurements. Despite the well-known lack in the harmonization and standardization of the currently commercially available cTnI methods, we found a good clinical concordance of cTnI determination on both systems.

KW - Biomarkers

KW - Cardiotoxicity

KW - Concordance

KW - Method evaluation

KW - Oncological setting

UR - http://www.scopus.com/inward/record.url?scp=84906231225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906231225&partnerID=8YFLogxK

U2 - 10.3109/00365513.2014.898325

DO - 10.3109/00365513.2014.898325

M3 - Article

VL - 74

SP - 385

EP - 391

JO - Scandinavian Journal of Clinical and Laboratory Investigation

JF - Scandinavian Journal of Clinical and Laboratory Investigation

SN - 0036-5513

IS - 5

ER -